April 23-25, 2019
Amsterdam
Workshop A
TUESDAY, 23RD APRIL 2019
09.00 - 12.00
Neoantigen Identification to Ensure Immunogenic & Clinically Relevant Neoantigens
Workshop Leader:
Michal Bassani-Sternberg,
Sternberg Director, Immunopeptidomics Unit Center of Experimental Therapeutics , CHUV
HLA binding affinity, T cell bioassays and Immunopeptidomics have all been recognised to have key advantages and disadvantages in the neoantigen selection process. Through the presentation of the latest case studies and structured discussions, attendees will leave with novel insights on neoantigen calling processes.
Join this workshop to learn and discuss:
- Key advances in in silico MHC ligand prediction through mass spectrometry data
- Minimizing time and cost of the neoantigen selection, prediction and validation process
- Challenges and improvements in predicting the T-cell reponse
Michal Bassani-Sternberg, Sternberg Director, Immunopeptidomics Unit Center of Experimental Therapeutics , CHUV
Michal Bassani-Sternberg is heading the Immunopeptidomics unit that is integrated within the Center of Experimental Therapeutic (CTE) in the department of Oncology at the CHUV, Lausanne, Switzerland, where she integrates mass spectrometry based immunopeptidomics into the innovative translational clinical strategy of personalized immunotherapy. In the last ten years, Dr Bassani-Sternberg has focused her research mainly on the development of methodologies for highly accurate and in-depth immunopeptidomics. She has completed her PhD at the Faculty of Biology at the Technion – Israel Institute of Technology and post-doctorate at the Proteomics and Signal Transduction Department, headed by Prof. Matthias Mann at the Max Planck Institute of Biochemistry. Recently she has integrated next generation sequencing with immunopeptidomics to directly identify patient’s specific neo-epitopes presented on melanoma tissues.
Workshop B
TUESDAY, 23RD APRIL 2019
13.00 - 16.00
Regulatory Pathway & Landscape for Neoantigen-based Cancer Immunotherapy
Workshop Leader:
Asterios Tsiftsoglou,
Committee for Advanced Therapies Member, European Medicines Agency
As the cell therapy and cancer vaccine space advances and clinical investigations continue to produce promising results, uncertainty about the regulatory frameworks and procedures in place needs to be addressed.
In this workshop, attendees will learn and discuss:
- Current regulatory requirements in the clinical development and manufacturing of neoantigen based cancer immunotherapy
- Requirements to demonstrate convincing efficacy in neoantigen targeting
- What are the key considerations to take into account when working with regulatory body?
Asterios Tsiftsoglou, Committee for Advanced Therapies Member, European Medicines Agency
Dr Asterios Tsiftsoglou is currently a member of Committee for Advanced Therapies at the European Medicines Agency. He is also a Professor of Pharmacology at the Department of Pharmaceutical Sciences at Aristotle University of Thessaloniki. Prior to his current position, he was Assistant Professor of Medicine (Hematology-Oncology) at Harvard Medical School. Dr Tsiftsoglou obtained his M.Sci. and PhD in Pharmacology from Yale University. and carried out Postdoctoral Research in the Center for Cancer Research at MIT, Cambridge, MA.USA
